Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.11.5735

Clinical Characteristics, Treatment and Survival Outcomes in Malignant Mesothelioma: Eighteen Years' Experience in Turkey  

Berk, Serdar (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
Dogan, Omer Tamer (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
Kilickap, Saadettin (Department of Medical Oncology, Faculty of Medicine, Cumhuriyet University)
Epozturk, Kursat (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
Akkurt, Ibrahim (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
Seyfikli, Zehra (Department of Chest Diseases, Faculty of Medicine, Cumhuriyet University)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.11, 2012 , pp. 5735-5739 More about this Journal
Abstract
Background: Malignant mesothelioma (MM) is an insidious tumor with poor prognosis, arising from mesothelial surfaces such as pleura, peritoneum and pericardium. We here aimed to evaluate the demographic, clinical, and radiological features of patients with MM followed in our center as well as their survival. Methods: The study included 228 patients (131 male, 97 female) who were followed up in our institution between 1993 and 2010 with the diagnosis of MM. Results: The mean age was 59.1 years in men and 58.7 years in women and the sex ratio was 1.4:1 in favor of males. Environmental asbestos exposure was present in 86% of the patients for a mean duration of $40{\pm}20$ years (range: 3-70). Pleural effusion and thoracic/abdominal pain were the most common presenting signs and symptoms (70.2% and 57.8%, respectively). One hundred-thirteen (66%) patients were treated with platinum-based combination chemotherapy (PBCT) plus supportive care (SC) and 67 (34%) patients received SC alone. The median follow-up time was 10.0 months. The median overall survival was significantly improved with PBCT plus SC compared to SC alone (11.4 vs. 5.1 months; p=0.005). The 6, 12, 18, and 24-month survival rates were significantly improved with PBCT plus SC compared to SC alone (72%, 43%, 19%, and 2% vs. 49%, 31%, 11%, and 1%). Conclusion: The survival of patients with MM improved in patients treated with PBCT. The survival advantage continued 12- and 24-month after the initial time of combination chemotherapy.
Keywords
Malignant mesothelioma; asbestos; chemotherapy; supportive care;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Adams RF, Gray W, Davies RJ, Gleeson FV (2001). Percutaneous image-guided cutting needle biopsy of the pleura in the diagnosis of malignant mesothelioma. Chest, 120, 1798-802.   DOI
2 Al-Shimemeri AA, Al-Ghadeer HM, Giridhar HR (2003). Diagnostic yield of closed pleural biopsy in exudative pleural effusion. Saudi Med J, 24, 282-6.
3 Beauchamp HD, Kundra NK, Aranson R, Chong F, MacDonnell KF (1992). The role of closed pleural needle biopsy in the diagnosis of malignant mesothelioma of the pleura. Chest, 102, 1110-2.   DOI
4 Bianchi C, Brollo A, Ramani L, Bianchi T, Giarelli L (2001). Asbestos exposure in malignant mesothelioma of the pleura: a survey of 557 cases. Ind Hlth, 39, 161-7.   DOI
5 Bianchi C, Bianchi T (2007). Malignant mesothelioma: global incidence and relationship with asbestos. Ind Hlth, 45, 379-87.   DOI
6 Chakrabarti B, Ryland I, Sheard J, Warburton CJ, Earis JE (2006). The role of Abrams percutaneous pleural biopsy in the investigation of exudative pleural effusions. Chest, 129, 1549-55.   DOI   ScienceOn
7 Herndon JE, Green MR, Chahinian AP, et al (1998). Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest, 113, 723-31.   DOI   ScienceOn
8 Hughes RS (2005). Malignant pleural mesothelioma. Am J Med Sci, 329, 29-44.   DOI
9 Ismail-Khan R, Robinson LA, Williams CC Jr, et al (2006). Malignant pleural mesothelioma: a comprehensive review. Cancer Control, 13, 255-63.   DOI
10 Law MR, Gregor A, Hodson ME, Bloom HJ, Turner-Warwick M (1984). Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax, 39, 255-9.   DOI
11 Lee CW, Murray N, Anderson H, Rao SC, Bishop W (2009). Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer, 64, 308-13.   DOI
12 Marinaccio A, Binazzi A, Cauzillo G, et al (2007). Analysis of latency time and its determinants in asbestos-related malignant mesothelioma cases of the Italian register. Eur J Cancer, 43, 2722-8.   DOI
13 Metintas M, Hillerdal G, Metintas S (1999). Malignant mesothelioma due to environmental exposure to erionite: follow-up of a Turkish emigrant cohort. Eur Respir J, 13, 523-6.   DOI
14 Metintas M, Hillerdal G, Metintas S, Dumortier P (2010). Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. Arch Environ Occup Hlth, 65, 86-93.   DOI
15 Moore AJ, Parker RJ, Wiggins J (2008). Malignant mesothelioma. Orphanet J Rare Dis, 3, 34.   DOI
16 Pistolessi M, Rusthoven J (2004). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. Chest, 126, 1318-29.   DOI   ScienceOn
17 MTA (General Directorate of Mineral Research and Exploration). Mineral map of Sivas. http://www.mta.gov.tr/v2.0/turkiye_maden/il_maden/pdf_2010/sivas.pdf [Last accessed in 31.10.2012].
18 Muers MF, Stephens RJ, Fisher P, et al (2008). Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet, 371, 1685-94.   DOI
19 Pasetto R, Comba P, Marconi A (2005). Mesothelioma associated with environmental exposures. Med Lav, 96, 330-7.
20 Rahman NM, Gleeson FV (2008). Image-guided pleural biopsy. Curr Opin Pulm Med, 14, 331-6.   DOI
21 Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES (1997). The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest, 111, 106-9.   DOI   ScienceOn
22 Rusch VW, Rosenzweig K, Venkatraman E, et al (2001). A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 122, 788-95.   DOI
23 Ruth VS, Baas P, Zoetmulder FA (2003). Surgical treatment of malignant pleural mesothelioma. A review. Chest, 123, 551-61.   DOI
24 Scherpereel A, Astoul P, Baas P, et al (2010). Guideline of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J, 35, 479-95.   DOI   ScienceOn
25 Sterman DH, Litzky LA, Albelda SM (2008). Malignant mesothelioma and other primary pleural tumors. In: Fishman AP, Elias JA (eds.) Fishman's Pulmonary Diseases and Disorders, 4th ed. McGraw-Hill, Philadelphia, pp1535-52.
26 Senyigit A, Coskunel M, Topcu F, Isik R, Babayigit C. (2000). Malignant Pleural Mesothelioma: Evaluation of Clinical, Radiological and Histological Features in 136 Cases. Tuberculosis and Thorax, 48, 26-34.
27 Skammeritz E, Omland LH, Johansen JP, Omland O (2011). Asbestos exposure and survival in malignant mesothelioma: a description of 122 consecutive cases at an occupational clinic. Int J Occup Environ Med, 2, 224-36.
28 Stahel RA, Weder W, Lievens Y, Felip E; ESMO Guideline Working Group (2010). Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol, 21, 126-8.   DOI
29 Sugarbaker DJ, Flores RM, Jaklitsch MT, et al (1999). Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117, 54-65.   DOI
30 van Thiel ER, Surmont VF, van Meerbeeck JP. Malignant pleural mesothelioma: when is radiation therapy indicated? Expert Rev Anticancer Ther, 11, 551-60.
31 Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44.   DOI   ScienceOn
32 Walters J, Maskell NA (2011). Biopsy techniques for the diagnosis of mesothelioma. Recent Results Cancer Res, 189, 45-5.   DOI
33 Wang ZJ, Reddy GP, Gotway MB, et al (2004). Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics, 24, 105-19.   DOI   ScienceOn
34 Yilmaz UM, Utkaner G, Yalniz E, Kumcuoglu Z (1998). Computed tomographic findings of environmental asbestosrelated malignant pleural mesothelioma. Respirology, 3, 33-8.   DOI